Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTRACT-3: Buloxibutid in COVID-19
NCT04880642Phase 3Completed
- Sponsor
- Vicore Pharma
- Start
- Sep 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of buloxibutid in coronavirus disease 2019 (COVID-19), sponsored by Vicore Pharma. Started Sep 2021; status: completed.
02
Drugs
buloxibutid
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04880642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04880642.